ArticleFrontiers in pharmacology2021
Astragaloside IV Attenuates the Myocardial Injury Caused by Adriamycin by Inhibiting Autophagy.
Article in Frontiers in pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 36 citations in OpenAlex.
- Astragaloside IV attenuates arsenic trioxide-induced cardiac toxicity in rats via the p38 MAPK/NF-κB signaling pathway.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Autophagic therapeutic targeting for Doxorubicin-induced cardiomyopathy.Molecular biology reports · 2026Review
- Astragaloside IV attenuates high-glucose-Induced peritoneal fibrosis via modulation of the ENKUR/PI3K/Akt signalling pathway.PloS one · 2026Article
- Biomimetic astragaloside-IV-loaded mesoporous silica nanoparticles for treatment of dilated cardiomyopathy.Frontiers in pharmacology · 2026Article
- Astragaloside IV attenuates uremia-induced myocardial injury by inhibiting autophagy via ATF4.Scientific reports · 2025Article
- Beyond Traditional Use: The Scientific Evidence for the Role ofPharmaceuticals (Basel, Switzerland) · 2025Review
- Research Progress on Chemical Components ofMolecules (Basel, Switzerland) · 2025Review
- Therapeutic potential and mechanistic insights of astragaloside IV in the treatment of arrhythmia: a comprehensive review.Frontiers in pharmacology · 2025Review
- Astragaloside IV Attenuates Chronic Prostatitis by Activating Keap1/Nrf2/HO-1 Pathway: Suppressing Ferroptosis and Enhancing Antioxidant Defense.Journal of inflammation research · 2025Article
- Astragaloside IV Alleviates HCardiovascular therapeutics · 2025Article
- Astragaloside IV induces endothelial progenitor cell angiogenesis in deep venous thrombosis through inactivation of PI3K/AKT signaling.Histology and histopathology · 2024Article
- Astragaloside IV attenuates sunitinib-associated cardiotoxicity by inhibiting COUP-TFII.Heliyon · 2024Article
- Astragaloside IV protects LO2 cells from oxidative damage caused by radiation-induced bystander effect through Akt/Nrf2 pathway.Toxicology research · 2023Article
- The Role of Hydrogen Sulfide in Regulation of Cell Death following Neurotrauma and Related Neurodegenerative and Psychiatric Diseases.International journal of molecular sciences · 2023Review
- Review on the protective mechanism of astragaloside IV against cardiovascular diseases.Frontiers in pharmacology · 2023Review
- Comparative efficacy and pharmacological mechanism of Chinese patent medicines against anthracycline-induced cardiotoxicity: An integrated study of network meta-analysis and network pharmacology approach.Frontiers in cardiovascular medicine · 2023Article
- Hydrogen sulfide alleviates hypothyroidism-induced myocardial fibrosis in rats through stimulating autophagy and inhibiting TGF-β1/Smad2 pathway.The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology · 2023Article
- Review of the pharmacological effects of astragaloside IV and its autophagic mechanism in association with inflammation.World journal of clinical cases · 2022Review
- Therapeutic Potential of Astragaloside IV Against Adriamycin-Induced Renal Damage in RatsFrontiers in pharmacology · 2022Article
- Astragaloside IV Ameliorates Isoprenaline-Induced Cardiac Fibrosis in MiceFrontiers in cellular and infection microbiology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Astragaloside IV (ASIV) is the main active component of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.